Drugs / Talampanel
Trials 12 · a red edge is where a trial was stopped
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-05-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS) tevapharm.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talampanel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036296 ↗ |
| Known as | [14C] Talampanel | “Talampanel (non-radiolabeled), [14C] Talampanel” NCT00868361 ↗ |
| Known as | GYKI-53773 | ChEMBL registry synonym — accepted as the source's own label CHEMBL61872 ↗ |
| Known as | LY300164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004576 ↗ |
| Known as | TLP | “A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.” NCT00034814 ↗ |
| Action | Inhibit | “Talampanel is a drug which blocks these receptors.” NCT00036296 ↗2“Glutamate receptor ionotropic, AMPA 1 antagonist” CHEMBL61872 ↗ “Glutamate receptor ionotropic, AMPA 2 antagonist” CHEMBL61872 ↗ |
| Modality | Small molecule | — CHEMBL61872 ↗ |
| Route | Oral | “One will take LY300164 3 times a day, along with levodopa, for 3 weeks.” NCT00004576 ↗ |
| Target | GRIA1 | “Glutamate receptor ionotropic, AMPA 1 antagonist” CHEMBL61872 ↗ |
| Target | GRIA2 | “Glutamate receptor ionotropic, AMPA 2 antagonist” CHEMBL61872 ↗ |